and Glenn, everyone. morning, Thanks, good
in New would XX:XX mentioned, York XX like September we Therapy from that to Day hosting Glenn remind X:XX on first everyone Gene a.m. As I to Friday, are Investor R&D a.m. our
our update gene will detail. We an in more portfolio review therapy provide and
will our and programs be retinal inherited therapy joined their their highly the diseases. recognized by potential who gene for key therapy orphan diseases, insights provide opinion gene retinal scientists will treatment leaders of and We in regarding
at We Chair, a Cell include; share Director Society from Beltran Hospital from Philadelphia; Eye are Khanna of UMass; Dr. from A. Alfred Department Guangping President of to Director Bart Dr. & Center Dr. the Duke Chair Charles with Clinic, speakers, from P. Ophthalmology of Aguirre Gao, Dr. at Gene Dr. Head you our Horae American of Ophthalmology Casey the University Andreas Ghent University University; Gene which William Dr. from list Children's and of of Institute; Therapy, UMass; excited Dr. Hemant Lewin of Lauer, and at Gustavo Therapy UPenn; and of Degenerations of of the Retinal Department Florida. Dr. Leroy, UPenn; Gersbach
of to UPenn and Therapy strengthen University and Gene continue the Horae Center, scientific We our relationship expand with cultivate, its the and investigators the UMass Florida. at
have scientists we We with our made collaborating programs. the we're of in and privilege with retinal the in pioneers progress leading and gene have delighted therapy,
will to R&D Investor meet of them our have the You many Day. during opportunity Gene Therapy
in for Penn, with In study to a The IC-XXX preclinical progress are on with we continue and history track, we is and rhodopsin-mediated conducting IND-enabling study collaboration natural activity. preclinical development patients. adRP program
Process manufacturer preclinical track for Paragon and currently as we development planned manufacturing engaged clinical our of GMP-grade on I/II are Phase Glenn and and supply ongoing. As mentioned for IC-XXX. have activities earlier, materials
a ocular sites clinical few the is degenerative experienced clinical in retinal to leading Our strategy while trial diseases field surgery. therapy retinal also select in have of specialists gene
initiate there and IC-XXX XXXX. We to FDA an of to Currently, our or continue a available Phase the clinical the during no of trial are patients advance potential have IND EMA-approved towards second identified options trial adRP. for filing and treatment I/II clinical rhodopsin-mediated sites treatment with half
study natural BESTX-related are history IRD. study with IC-XXX. additional conducting Penn, Regarding in with and In preclinical collaboration we patients
Phase for We Paragon also and other for process I/II of commenced preclinical development, material GMP-grade have IND-enabling and IC-XXX. manufacturing clinical supply manufacturer is our our planned activities.
We options FDA expect initiate the Phase XXXX. EMA-approved to for of or treatment with no BESTX-related in available IC-XXX I/II patients first clinical trial for there a Currently, are IRDs. half
one to deliver AAV smaller limitations functional vector Employing gene of this are strategy their attractive and packaging the transgene overcome leading the for a of a choice Although but main an is therapy, vectors option is limitation retinal delivery Khanna minigene standard-sized of therapy at at A portion And we UMass. is packaging are Gao Drs. them. in collaborate Therapy larger retinal primary and minigene headed in to by excited vector. research AAV with the the Center capacity. transgene Horae Gene
and of vectors our believe We RP. miniCEPXXX and results for the potential nonsyndromatic encouraging syndrome XA treatment supports have recently most out, assessing As in disease USHXA-related Glenn we autosomal Usher currently diseases, inherited technology type from are autosomal new mutation-independent LCAXX, expanded recessive LCAXX. including the our of minigene retinal AAV Stargardt USHXA-associated recessive program pointed in pipeline and the this that
would We and product update with a Gene during Investor of be preclinical Day. advanced you continue Therapy to IND-enabling our development through plan identifying goal construct which R&D optimize to lead activities. further the the We candidate,
Our currently miniABCAX autosomal XXXX. results recessive expect Stargardt and disease program also minigene in ongoing, is for research to receive we
condition Usher an a syndrome These and USHXA-associated with USHXA-associated without condition adolescence syndrome is hearing diseases due that retinal that recessive loss RP hearing RP. nonsyndromatic pigmentosa Usher vision adulthood. XA autosomal pigmentosa associated inherited birth in global vision characterized nonsyndromatic as associated progressive autosomal loss retinitis loss IRD genetic include or recessive a type are in retinitis begins orphan USHXA-related by loss. genetic mutations gene. with autosomal recessive USHXA and type associated from XA to manifests is
treatment currently focused with USHXA vision deliverable developing loss on mutation. minigene a option the mutation-independent associated We the are for
therapies to USHXA-associated or syndrome XA recessive no There Usher FDA LCAXX, type Stargardt or are autosomal nonsyndromatic disease, recessive currently EMA-approved autosomal treat RP.
addition vision with is common most common to autosomal-dominant seeking disease. USHXA retinal forward recessive the pigmentosa, is our progress. treat retinitis common look pigmentosa loss investors pigmentosa, Retinitis our portfolio, to and form rhodopsin-mediated With continues of to most orphan updating USHXA-related. We portfolio most of reportedly the autosomal form bio what of the associated inherited the retinitis are IVERIC the program to as
Thank I Carroll. over you now time. for Dave call the turn will Dave? to your